Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:1901-1909

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brand, K.
Right arrow Articles by Neumeier, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brand, K.
Right arrow Articles by Neumeier, D.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*HYDROGEN PEROXIDE
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:1901-1909.)
© 1997 American Heart Association, Inc.


Articles

Dysregulation of Monocytic Nuclear Factor-{kappa}B by Oxidized Low-Density Lipoprotein

Korbinian Brand; Tamara Eisele; Ursula Kreusel; Michael Page; Sharon Page; Monika Haas; Astrid Gerling; Christian Kaltschmidt; Franz-Josef Neumann; Nigel Mackman; Patrick A. Baeuerle; Autar K. Walli; ; Dieter Neumeier

From the Institute of Clinical Chemistry and Pathobiochemistry (K.B., T.E., U.K., M.P., S.P., M.H., D.N.) and the Department of Internal Medicine I (F.J.N.), Klinikum rechts der Isar, Technical University Munich (Germany); the Institute of Clinical Chemistry (A.G., A.K.W.), Klinikum Grosshadern, Ludwig-Maximilians University Munich (Germany); the Institute of Biochemistry (C.K.), Albert-Ludwigs University, Freiburg, Germany; the Departments of Immunology and Vascular Biology (N.M.), the Scripps Research Institute, La Jolla, Calif; and Tularik Inc (P.A.B.), South San Francisco, Calif.

Correspondence to Dr Korbinian Brand, Institute of Clinical Chemistry and Pathobiochemistry, Klinikum rechts der Isar, Technical University Munich, Ismaninger Str 22, D-81675 München, Germany.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract Nuclear factor-{kappa}B (NF-{kappa}B)/Rel transcription factors may be involved in atherosclerosis, as is suggested by the presence of activated NF-{kappa}B in human atherosclerotic lesions. The aim of the present study was to investigate the effects of oxidized LDL (oxLDL) on the NF-{kappa}B system in human THP-1 monocytic cells as well as adherent monocytes. Our results demonstrate that short-term incubation of these cells with oxLDL activated p50/p65 containing NF-{kappa}B dimers and induced the expression of the target gene IL-8. This activation of NF-{kappa}B was inhibited by the antioxidant and H2O2 scavenger pyrrolidine dithiocarbamate and the proteasome inhibitor PSI. The oxLDL-induced NF-{kappa}B activation was accompanied by an initial depletion of I{kappa}B-{alpha} followed by a slight transient increase in the level of this inhibitor protein. In contrast, long-term treatment with oxLDL prevented the lipopolysaccharide-induced depletion of I{kappa}B-{alpha}, accompanied by an inhibition of both NF-{kappa}B activation and the expression of tumor necrosis factor-{alpha} and interleukin-1ß genes. These observations provide additional evidence that oxLDL is a potent modulator of gene expression and suggest that (dys)regulation of NF-{kappa}B/Rel is likely to play an important role in atherogenesis.


Key Words: nuclear factor-{kappa}B • oxidized LDL • reactive oxygen intermediates • I{kappa}B-{alpha} • monocytes • macrophages


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
The pleiotropic transcription factor nuclear factor-{kappa}B (NF-{kappa}B)/Rel is present in the cytosol in an inactive state bound to inhibitory proteins collectively termed I{kappa}B.1 2 The prototypic NF-{kappa}B dimer consists of the subunits p50 and p65, although other subunits such as c-Rel have been described.3 4 Several I{kappa}B proteins have been identified, including I{kappa}B-{alpha} and I{kappa}B-ß.5 6 Activation of NF-{kappa}B is induced by a variety of agents including inflammatory or lymphoproliferative cytokines, reactive oxygen intermediates, microbial pathogens, and viruses.5 7 This activation of NF-{kappa}B involves phosphorylation of I{kappa}B and proteolysis of this inhibitor by a large protease complex, the proteasome, followed by nuclear translocation of the dimer.4 5 In the nucleus, activated NF-{kappa}B interacts with regulatory {kappa}B DNA elements in promoters and enhancers, thereby controlling the inducible gene transcription of a plethora of genes involved in inflammation and proliferation.5 7

It has been suggested that NF-{kappa}B may play an important role in atherosclerosis by modulating gene expression in cells participating in lesion formation.8 9 10 We have recently demonstrated the presence of activated NF-{kappa}B in monocyte/macrophages, smooth muscle cells, and endothelial cells of human atherosclerotic lesions in vivo.11 A variety of genes are induced in the atherosclerotic lesion and/or proposed to be involved in atherogenesis12 that are known to be regulated by NF-{kappa}B in cultured cells, including the genes encoding TNF-{alpha}5 13 ; IL-1,14 IL-6,5 and IL-85 15 ; the granulocyte/macrophage-colony stimulating factors (G-CSF, M-CSF, and GM-CSF)5 16 17 ; monocyte chemotactic protein-1 (MCP-1)5 18 19 ; tissue factor20 21 22 23 ; several adhesion molecules5 24 25 26 27 ; and c-myc.28

oxLDL has been identified as a major component of the early as well as advanced atherosclerotic lesion, and numerous studies have demonstrated a variety of effects of this lipoprotein on different cell functions9 29 30 including gene expression in several cell types involved in atherogenesis.31 32 33 34 35 36 37 Recent studies indicate that NF-{kappa}B is involved in mediating the effects of oxLDL on gene expression: However, cultured human endothelial cells are the only cell type in which an oxLDL-induced activation of NF-{kappa}B has been so far described.38 39 In contrast, recent reports have found an inhibition of LPS-induced NF-{kappa}B activation by long-term treatment with oxLDL in macrophages and smooth muscle cells.40 41 42

The aims of the present study were, therefore, to test whether oxLDL can activate NF-{kappa}B in cells of the monocytic lineage under certain conditions and to investigate the effects of oxLDL on the NF-{kappa}B system more thoroughly in order to understand the underlying mechanisms that produce the apparently conflicting results in the literature described above. Using human THP-1 monocytic cells and ex vivo isolated adherent monocytes, we demonstrated that short term exposure to oxLDL activated NF-{kappa}B and associated target gene expression, whereas after long-term incubation with these lipoproteins an inhibition of the NF-{kappa}B system was observed. Both opposing effects were further characterized using specific antibodies and inhibitors and by investigation of the fate of the NF-{kappa}B inhibitor protein I{kappa}B-{alpha}. A potential role of aberrant NF-{kappa}B/Rel regulation by oxLDL in the pathology of atherosclerosis is discussed.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Culture and Reagents
THP-1 monocytic cells (DSM) were maintained in suspension at a density of 2x105 to 1x106/mL in RPMI-1640 (Glutamax-1, low endotoxin; GibcoBRL) containing 7% fetal calf serum (Myoclone super plus, low endotoxin; GibcoBRL) and 100 U/mL penicillin/100 µg/mL streptomycin (GibcoBRL). For some experiments, THP-1 cells were differentiated into macrophage-like cells using phorbol myristate acetate (Sigma) at a concentration of 10-7 mol/L.43 For the experiments, the cells were incubated in 25 cm2 tissue culture flasks (3x106 cells/flask) or plated at a density of 5x106 cells per well in six-well culture dishes as described.43 Peripheral blood mononuclear cells were isolated from blood samples of normal donors by the Ficoll-Hypaque method as described.33 Monocytes were isolated from mononuclear cells by adherence (3-hour adherence, nonadherent cells were subsequently removed by washing 3 times) to achieve a purity of approximately 90% as determined by flow cytometry. The adherent monocytes were cultured for 20 hours in the same medium as THP-1 cells but with 5% fetal calf serum before the experiment was started. LPS (Escherichia coli 0111:B4) was purchased from Sigma. Viability of cells was monitored by trypan blue dye exclusion. PDTC was obtained from Sigma, PSI from Peptide Institute Inc, and tricyclodecan-9-yl xanthate (D609) from Biomol. A monoclonal mouse anti-human monocyte CD14 antibody was obtained from Dako.

Lipoprotein Isolation, Modification, and Characterization
LDL (d=1.019 to 1.063 g/mL) was isolated from human plasma of normolipidemic healthy volunteers by sequential ultracentrifugation as described33 and stored in PBS containing 2 mmol/L EDTA. Immediately before oxidation, the EDTA was removed from LDL by passing the lipoprotein through a PD 10 column (Pharmacia). LDL was oxidized in Ham's F-10 medium by exposure to 5 µmol/L CuSO4 at 37°C.44 33 Slightly modified LDL was also obtained by long-term storage at 4°C34 or exposure of the LDL to monocytic cells.44 Equivalent effects were found with dialyzed and nondialyzed preparations (data not shown). For the presented experiments, the preparations were dialyzed before they were added to the cultured cells. Acetylated LDL was prepared by treatment of LDL with acetic anhydride as described earlier.45 The protein concentration was determined by the Lowry method45 and the cholesterol content by the cholesterol-assay from Boehringer Mannheim. Thiobarbituric acid reactive substances (TBARS) were measured as described33 46 and the initial TBARS value of native LDL was <0.1 nmol malondialdehyde equivalents/mg of protein (7 preparations). Unless otherwise stated, mildly to moderately oxidized forms of oxLDL were used for the experiments which were modified by short time exposure to CuSO4 (TBARS values ranging from 1.94 to 5.37 nmol/mg). Precautions taken to prevent endotoxin contamination during lipoprotein isolation and oxidation and experimental procedures included the use of pyrogen-free sterile water, reagents, and culture dishware. Endotoxin contamination was screened by the limulus amoebocyte lysate assay (Labortechnik Peter Schultz) and the Kinetic-QCL-test (BioWhittaker) and only lipoprotein preparations with an endotoxin content of <10 pg/mL were used for the experiments. As an additional control, some preparations were passed through a column containing the Affinity Pak Detoxi-Gel, which removes endotoxin.

Exclusion of Toxic Effects of Lipoproteins
A potential toxic effect of LDL and oxLDL on the cells was investigated by trypan blue exclusion, which demonstrated that >98% of the cells were trypan blue negative in the presence of the lipoproteins. In addition, toxicity of the reagents on the cells was monitored by the WST-1 test (Boehringer Mannheim), which confirmed that the lipoproteins were not toxic under the conditions used in our experiments (TableDown). Furthermore, the adherence of monocytes in the presence of LDL or oxLDL was not affected up to 48 hours as determined by counting the cells that remained attached (data not shown).


View this table:
[in this window]
[in a new window]
 
Table 1. Metabolic Activity of Cells Exposed to Lipoproteins

Electrophoretic Mobility Shift Assay
Nuclear extracts from 5x106 cells were prepared and analyzed as described previously.22 Protein concentrations were determined by the Bradford method (BioRad). The prototypic immunoglobulin {kappa}-chain oligonucleotide was used as a probe (5'-CAGAGGGACTTTCCGAGA-3')5 and labeled by annealing of complementary primers followed by primer extension with the Klenow fragment of DNA polymerase I (Boehringer Mannheim) in the presence of [{alpha}-32P]dCTP (>3000 Ci/mmol; DuPont) and deoxynucleoside triphosphates (Boehringer Mannheim). Nuclear extracts (5 µg protein) were incubated with radiolabeled DNA probes ({approx}10 ng; 105 cpm) for 30 minutes at room temperature in 20 µL of binding buffer (20 mmol/L Tris-HCl, pH 7.9; 50 mmol/L KCl; 1 mmol/L dithiothreitol; 0.5 mmol/L EDTA; 5% glycerol; 1 mg/mL BSA; 0.2% NP-40; 50 ng of poly(dI-dC)/µL). Samples were run in 0.25x TBE buffer (10x 890 mmol/L Tris; 890 mmol/L boric acid; 20 mmol/L EDTA, pH 8.0) on nondenaturing 4% or 6% polyacrylamide gels at 125 V. Nuclear extracts from LPS-stimulated THP-1 cells and Hela cells were used as positive controls. As an additional control, samples were incubated with an excess (10x, 100x) of nonlabeled {kappa}B oligonucleotide, which completely abolished binding of the radiolabeled oligonucleotide to the nuclear proteins. To control the nuclear protein content, the nuclear extracts were incubated with a blunt end double-stranded Sp-1 oligonucleotide that was labeled with [{gamma}-32P]ATP (>5000 Ci/mmol, DuPont) and T4 polynucleotide kinase (Boehringer Mannheim). Gels were dried and analyzed by autoradiography.

Supershift Analysis
The nuclear extracts were incubated with 2 µL of appropriate TransCruz gel supershift antibodies (Santa Cruz Biotechnology) per 20 µL of reaction volume at 4°C or room temperature for 2 hours. The following rabbit polyclonal supershift antibodies were used: anti-p50 (recognizing part of the basic nuclear location sequence and the N-terminal adjacent 11 amino acids of the p105 precursor), anti-p65 (raised against a peptide corresponding to amino acids 3-19 within the N-terminal region) and anti–c-Rel (recognizing amino acids 152-176 within the N-terminal domain). This incubation step was followed by EMSA as described above.

Immunocytochemistry
Immunocytochemistry was performed to examine the labeling for activated NF-{kappa}B within cells. The antibody used was {alpha}-p65MAb (11 Boehringer-Mannheim), which recognizes an epitope on the p65 subunit of NF-{kappa}B that is masked by the bound inhibitor I{kappa}B. Therefore, this antibody reacts only with the activated I{kappa}B released form of NF-{kappa}B. After incubation with lipoproteins, the cells were harvested by centrifugation, washed three times with PBS, and bound to adhesion slides (BioRad). After fixation with reagent A of the Fix and Perm kit (An der Grub) at a dilution of 1:2 in PBS, nonspecific antibody binding was blocked with 0.2% bovine serum albumin (BSA) and the cells incubated for 2 hours at 4°C with the {alpha}-p65MAb antibody at a dilution of 1:500 in PBS with 0.25% reagent B (Fix and Perm kit) to aid permeabilization. The cells were then incubated with a biotinylated goat anti-mouse secondary antibody (Dianova) followed by ABC (avidin biotin horseradish peroxidase complex) (Zymed) both for 30 minutes at room temperature, before visualization with benzidine dihydrochloride (BDHC) (0.01% wt/vol). The slides were dehydrated and mounted in DePex (Fluka) before photography.

Transfection of THP-1 Cells
A luciferase reporter plasmid (pGL2 Basic, Promega) containing 420 bp of the 5'-upstream region of the IL-8 gene (pGL2 IL-8) was transiently cotransfected with a Renilla luciferase control plasmid (pRLtK, Promega) into THP-1 cells using a DEAE-dextran–based protocol.22 Cells were plated out after transfection to a density of 2x106/3 ml in a 6-well plate and kept at 37°C, with 5% CO2. After 2 days the cells were incubated for 5 hours with LDL, oxLDL, or without lipoproteins. A plasmid lacking the 5'-upstream region of the IL-8 gene was used as a specificity control (pGL2 Basic, Promega). Subsequent to stimulation the cells were harvested by centrifugation and washed once with PBS. Lysis was performed in 1x Passive Lysis Buffer (Promega) for 15 minutes at room temperature. The luciferase activity in the resulting protein lysates was measured using the Dual Luciferase Reporter Assay system (Promega), recording the firefly luciferase activity produced by the experimental plasmids and the Renilla luciferase activity produced by the constitutively active cotransfected control plasmid. The results are expressed as normalized (against the value for lysis buffer alone) firefly luciferase RLU divided by the normalized RLU values obtained for the Renilla luciferase, giving comparative data that account for any differences in transfection efficiency.

Polyacrylamide Gel Electrophoresis and Western Blot Analysis
Cytosolic extracts were isolated as described earlier.47 Electrophoresis was performed with 9% polyacrylamide gels (0.1% SDS) and carried out at 140 mA for 1.5 hours (separating gel) in a cooled system as previously described.43 The proteins were transferred to a nitrocellulose membrane using the wet blotting technique. After transfer, the nitrocellulose membranes were incubated with a polyclonal antibody raised against the carboxy terminal domain of the inhibitor I{kappa}B-{alpha} (Santa Cruz Biotechnology), followed by a peroxidase-conjugated polyclonal goat anti-rabbit IgG antibody (Dianova). Antibody binding to I{kappa}B-{alpha} was visualized on x-ray film using the enhanced chemiluminescence technique (Amersham). The protein size was confirmed by molecular weight standards.

Northern Blot Analysis
Total RNA was extracted from 5x106 cells by means of the micro RNA isolation kit (Stratagene). Northern blotting was performed essentially as described.21 Five micrograms total RNA was electrophoresed through a denaturing 1.2% formaldehyde gel and capillary blotted overnight onto nylon membranes (Boehringer Mannheim). Hybridization was carried out overnight at 42°C with probes that were labeled using the Multiprime DNA labeling system (Amersham). The blot was washed with increasingly stringent concentrations of SSC at 52°C and exposed to autoradiography film (Du Pont). To account for variability in sample loading, the blot was rehybridized with a GAPDH cDNA probe.

Determination of IL-8
Concentrations of IL-8 in cell supernatants were measured by sandwich-type immunoassay (Quantikine, R&D systems).


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Exposure to oxLDL Induces Activation and Nuclear Appearance of NF-{kappa}B
THP-1 monocytic cells were incubated in the presence of 80 µg protein/mL of either LDL or oxLDL and activation of NF-{kappa}B was measured by EMSA. In our previous dose-response experiments, it had been shown that this concentration of lipoprotein was effective for the modulation of NF-{kappa}B target gene expression in THP-1 cells and adherent monocytes.15 33 Exposure of cells to copper-modified oxLDL for 1 hour increased NF-{kappa}B activation in THP-1 monocytic cells (Fig 1ADown) that remained elevated for up to 12 hours (data not shown, see below). In the same extracts, we also examined the binding of nuclear proteins to an oligonucleotide comprising the Sp-1 consensus sequence, which was not affected by the oxLDL treatment. LDL modified by long-term storage at 4°C or cell-induced oxidation also activated NF-{kappa}B (data not shown). Little or no NF-{kappa}B activation was observed in cells incubated with LDL (Fig 1ADown) or acetylated LDL (data not shown). Similar results were obtained with phorbol ester-treated THP-1 macrophage-like cells in which a 3.0±0.9-fold (n=3) induction of NF-{kappa}B activity by oxLDL was measured.



View larger version (51K):
[in this window]
[in a new window]
 
Figure 1. Activation of NF-{kappa}B by oxLDL in monocytic cells. A, THP-1 cells were incubated for 1 hour in the absence of lipoproteins or with 80 µg/mL of oxLDL or LDL, respectively. Activation of NF-{kappa}B was determined by EMSA; bracket indicates the position of NF-{kappa}B bands. Binding of nuclear proteins to an oligonucleotide containing the Sp-1 consensus sequence was also examined in the same nuclear extracts (double arrow). B, Nuclear appearance of activated NF-{kappa}B in the presence of oxLDL. Activated NF-{kappa}B was detected by immunocytochemistry using the monoclonal antibody {alpha}-p65MAb (dilution 1:500) and BDHC staining, giving a blue-black color in the original micrograph and a granular staining pattern. The activated NF-{kappa}B appears to be present mostly in the nucleus of oxLDL-treated cells. Magnification x240. Co indicates control.

The nuclear appearance of oxLDL-activated NF-{kappa}B was also examined by immunocytochemistry. For this purpose, we used {alpha}-p65MAb, a monoclonal antibody that selectively detects activated NF-{kappa}B.11 In unstimulated cells, little staining was detected, indicating the presence of only low amounts of active p65-containing NF-{kappa}B dimers (Fig 1BUp). In the presence of oxLDL (12-hour incubation), we observed an increased nuclear staining of cells, suggesting increased activation and nuclear translocation of NF-{kappa}B, which corroborates our results from EMSA analysis. A staining pattern similar to that of the control was observed in the presence of LDL (data not shown). No staining was detected in the absence of the primary antibody or when an isotype control was used (data not shown).

NF-{kappa}B Activation by oxLDL and Associated Target Gene Expression in Adherent Monocytes
Next, we examined whether oxLDL activates NF-{kappa}B in ex vivo isolated human adherent monocytes. Human peripheral blood monocytes were isolated, adhered overnight, and subsequently incubated with the lipoproteins for 4 hours. As can be seen in Fig 2ADown, incubation with 80 µg/mL of oxLDL but not LDL activated NF-{kappa}B in these cells. We have recently shown that oxLDL induces the expression of IL-8 in adherent monocytes.15 Therefore, in the same set of experiments, the production of the NF-{kappa}B target gene IL-85 was monitored. In the presence of oxLDL, a significant increase in the synthesis of IL-8 compared with the control or the LDL-treated sample was observed under the same conditions in which NF-{kappa}B activation was detected (Fig 2Down, A and B). A similar induction of IL-8 production by oxLDL was observed in THP-1 cells (data not shown).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2. oxLDL induces NF-{kappa}B activation and associated target gene expression in adherent monocytes. Human adherent monocytes were incubated for 4 hours in the absence of lipoproteins or with 80 µg/mL of LDL or oxLDL, respectively. Activated NF-{kappa}B was measured by EMSA and is indicated by the bracket (A). In the same set of experiments the production of IL-8 in the supernatant was detected by immunoassay (B). Co indicates control.

IL-8 Promoter–Dependent Transcription Is Induced by oxLDL
To investigate whether oxLDL specifically induced IL-8 promoter-dependent transcription in our system, THP-1 cells were transiently transfected with a luciferase reporter construct containing 420 bp of the 5'-upstream region of the IL-8 gene. Incubation with oxLDL but not LDL significantly induced the transcription of this construct (Fig 3Down). A control plasmid lacking the IL-8 5'-region was not induced by oxLDL.



View larger version (21K):
[in this window]
[in a new window]
 
Figure 3. IL-8 promoter-dependent transcription is induced by oxLDL. THP-1 cells were transiently cotransfected with a luciferase reporter gene construct containing 420 bp of the 5'-region of the IL-8 gene (pGL2 IL-8) or lacking this region (pGL2 Basic) and pRLtk Renilla luciferase control plasmid. Transfected cells were incubated with LDL or oxLDL (80 µg/mL) for 5 hours. Data are expressed as firefly luciferase RLU divided by Renilla-RLU.

OxLDL Induces p50/p65 Containing NF-{kappa}B Dimers
To identify the NF-{kappa}B subunits in the protein/DNA complexes induced by oxLDL, polyclonal antibodies against the NF-{kappa}B subunits p50, p65, and c-Rel were used for supershift analysis of nuclear extracts from THP-1 cells (Fig 4ADown) and adherent monocytes (Fig 4BDown). Incubation with anti-p50 almost completely abrogated or supershifted the protein/DNA complexes in EMSA induced by oxLDL, indicating that the majority of the dimers contained a p50 subunit. Likewise, a similar effect was observed with anti-p65, whereas no inhibition was observed with anti–c-Rel. In conclusion, oxLDL appears to induce predominantly p50/p65 containing NF-{kappa}B dimers in human monocytic cells.



View larger version (33K):
[in this window]
[in a new window]
 
Figure 4. Composition of oxLDL-induced complexes. Nuclear extracts harvested from (A) oxLDL-treated THP-1 cells (1-hour incubation) and (B) adherent monocytes (4-hour incubation) were analyzed by supershift analysis. For this purpose, nuclear extracts were preincubated with polyclonal antibodies directed against p50, p65, and c-Rel or with p65 and c-Rel together. Brackets indicate position of the NF-{kappa}B bands. Arrows mark the positions of the bands shifted by preincubation with anti-p65 or anti-p50. No Ab indicates that no antibody was added for preincubation.

Effects of the Antioxidant PDTC and the Proteasome Inhibitor PSI
Various compounds were tested for their ability to modulate oxLDL-induced activation of the NF-{kappa}B system. To demonstrate an involvement of ROI in oxLDL-induced signaling and NF-{kappa}B activation, the cells were incubated with the antioxidant and H2O2 scavenger PDTC.48 49 As seen in Fig 5ADown, PDTC blocked the activation of NF-{kappa}B by oxLDL in a dose-dependent manner. Next, we tested the proteasome inhibitor PSI47 to investigate whether I{kappa}B-{alpha} proteolysis was involved in oxLDL-induced NF-{kappa}B activation. In cells pretreated with PSI for 1 hour, the oxLDL-induced NF-{kappa}B activation was strongly inhibited (Fig 5BDown). In the same experiments, the level of I{kappa}B-{alpha} was examined in cytosolic extracts by Western blot analysis. The data show that the oxLDL-induced activation of NF-{kappa}B at 1 hour was accompanied by a depletion of I{kappa}B-{alpha}, which was prevented by PSI in a similar dose range to that in which NF-{kappa}B activation was inhibited (Fig 5BDown). Under the experimental conditions used, the toxicity of PDTC and PSI was excluded by the WST-1 assay (data not shown).



View larger version (25K):
[in this window]
[in a new window]
 
Figure 5. Effects of the antioxidant PDTC and the proteasome inhibitor PSI. THP-1 cells were incubated in plain medium or with 80 µg/mL of oxLDL in the absence or presence of different concentrations of PDTC for 6 hours (A) or pretreated with increasing doses of PSI for 1 hour and then stimulated with lipoproteins for 1 hour (B). NF-{kappa}B was examined by EMSA; brackets indicate activated NF-{kappa}B. Cytosolic I{kappa}B-{alpha} was detected by Western blot analysis and is marked by arrows. Note that in most of the experiments the slower-migrating phosphorylated form of I{kappa}B-{alpha} could be detected as marked by the upper arrow of the doublet.

In contrast, neither the xanthate D609, an inhibitor of phosphatidylcholine-specific phospholipase C, which blocks TNF-induced NF-{kappa}B activation,50 nor antibodies against the LPS receptor CD 14 had an effect on oxLDL-induced NF-{kappa}B activation (data not shown).

Time Course of oxLDL-Induced NF-{kappa}B Activation and I{kappa}B-{alpha} Depletion
In several studies, cells were incubated with oxLDL for a longer period of time before gene expression was examined.36 37 Therefore, time course experiments were performed in which the cells were cultivated for up to 24 hours with oxLDL, and the activation of NF-{kappa}B and the level of I{kappa}B-{alpha} was monitored over time. Incubation with oxLDL induced the activation of NF-{kappa}B, which reached a maximal level at 1 hour, remained elevated at 6 hours, and returned to baseline by 24 hours (Fig 6Down). Under the same conditions, oxLDL caused an initial depletion of I{kappa}B-{alpha} by 1 hour followed by a transient slight increase in the level of this inhibitor by 6 hours. In the presence of LDL or in untreated cells, the I{kappa}B-{alpha} levels remained constant during the incubation intervals (data not shown).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 6. Time course of oxLDL-induced NF-{kappa}B activation and I{kappa}B-{alpha} depletion. THP-1 cells were incubated over 24 hours with 80 µg/mL of oxLDL. NF-{kappa}B activation was determined by EMSA and cytosolic I{kappa}B-{alpha} was detected by Western blot analysis. Data were analyzed by densitometry and are combined on a histogram. NF-{kappa}B activation is depicted as arbitrary units normalized against Sp-1 binding examined in the same extracts. For the I{kappa}B-{alpha} data, the level of this inhibitor in the untreated control (0 hours) was defined as the 100% value.

Loss of Inducible NF-{kappa}B Activation and Target Gene Expression After Long-term Exposure to oxLDL
It has been reported that a longer preincubation with oxLDL inhibits the inducible expression of the NF-{kappa}B target genes TNF-{alpha} and IL-1ß.36 37 To test whether long-term exposure to lipoproteins can alter the induced NF-{kappa}B activation in our system, the cells were cultured in the absence or presence of LDL or oxLDL for 24 hours followed by a 1-hour stimulation with 1 µg/mL LPS, a very potent stimulus for NF-{kappa}B activation in cells of the monocytic lineage. In cells preincubated with LDL, the LPS-induced NF-{kappa}B activation was not affected (Fig 7ADown). Preincubation with oxLDL, however, significantly reduced the activation of NF-{kappa}B by LPS. Little or no NF-{kappa}B activity was observed in cells exposed to LDL or oxLDL for 24 hours (data not shown). In the same extracts, we also investigated the binding of nuclear proteins to an Sp-1 oligonucleotide, which was not affected by long-term treatment with oxLDL (Fig 7ADown).



View larger version (42K):
[in this window]
[in a new window]
 
Figure 7. Long-term exposure to oxLDL inhibits LPS-induced NF-{kappa}B activation and target gene expression. A, Inhibition of LPS-induced NF-{kappa}B activation by oxLDL. THP-1 cells were preincubated in medium alone, 80 µg/mL LDL, or oxLDL for 24 hours followed by a 1-hour stimulation with 1 µg/mL LPS. Activated NF-{kappa}B, examined by EMSA, is indicated by a bracket. Binding of nuclear proteins to an oligonucleotide containing the Sp-1 consensus sequence was also examined in the same nuclear extracts (double arrow). B, Inhibition of LPS-induced TNF-{alpha} and IL-1ß mRNA expression by oxLDL. The cells were incubated as mentioned in A, with the only exception that total RNA was harvested for Northern blot analysis after a 3-hour stimulation with LPS. To account for variability in sample loading, the blot was rehybridized with a GAPDH cDNA probe.

Next, we examined whether long-term treatment with oxLDL affects the expression of the NF-{kappa}B target genes TNF-{alpha} and IL-1ß. The cells were preincubated with either LDL or oxLDL for 24 hour followed by stimulation with LPS for 3 hours, and total RNA was harvested for Northern blot analysis. As expected, stimulation with LPS induced mRNA expression for the two NF-{kappa}B target genes TNF-{alpha} and IL-1ß (Fig 7BUp). Exposure of cells to oxLDL but not LDL significantly inhibited the LPS-induced expression of both genes. These data demonstrate an inhibition of NF-{kappa}B by long-term exposure to oxLDL associated with a negative regulatory effect on NF-{kappa}B target gene expression in monocytic cells.

Long-term Exposure to oxLDL Prevents the Efficient Activation-Induced Depletion of I{kappa}B-{alpha}
The LPS-induced NF-{kappa}B activation and the expression of TNF-{alpha} and IL-1ß was inhibited in cells exposed to oxLDL for 24 hours (see Fig 7BUp). Therefore, the fate of the inhibitor I{kappa}B-{alpha} was examined in cells preincubated with oxLDL for 24 hours and then stimulated with LPS for 1 hour. As expected, incubation with LPS leads to a rapid proteolytic removal of I{kappa}B-{alpha} within 1 hour in the absence of lipoproteins (Fig 8Down). This effect, however, was not evident in cells pretreated with oxLDL. In contrast, the LPS-induced removal of I{kappa}B-{alpha} was only slightly affected by the presence of LDL (Fig 8BDown). Therefore, preincubation with oxLDL appears to prevent an efficient depletion of I{kappa}B-{alpha} after stimulation of cells.



View larger version (18K):
[in this window]
[in a new window]
 
Figure 8. Long-term exposure to oxLDL prevents the efficient activation-induced depletion of I{kappa}B-{alpha}. A, THP-1 cells were preincubated in medium alone or 80 µg/mL oxLDL for 24 hours followed by a 1-hour stimulation with 1 µg/mL LPS. Cytosolic I{kappa}B-{alpha} was determined by Western blot analysis and is indicated by the arrows. The slower migrating phosphorylated form of I{kappa}B-{alpha} that could be detected in most of the experiments is marked by the upper arrow of the doublet. The positions of the molecular weight (MW) marker proteins are indicated. B, Cells were preincubated in the absence of lipoproteins or with 80 µg/mL LDL or oxLDL for 24 hours and then stimulated with 1 µg/mL LPS for 1 hour. Cytosolic I{kappa}B-{alpha} was measured as described in A.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
An increasing body of data indicates that lipoproteins influence a variety of cellular functions, not just lipid metabolism.9 12 29 Many of the lipoprotein-induced effects on signal transduction and transcriptional regulation have not yet been characterized. Several studies suggest that oxLDL may play an important role in gene regulation by modulating the NF-{kappa}B system.

In our study, a short time exposure to mildly oxLDL activated transcription factor NF-{kappa}B in human THP-1 cells and adherent monocytes, whereas a longer preincubation (24 hours) with these lipoproteins inhibited the LPS-induced NF-{kappa}B activation. In endothelial cells it has been shown that short-term exposure to minimally or mildly oxLDL activates NF-{kappa}B.38 39 In human and mouse macrophages, a long-term incubation (22 to 24 hours) with mildly and highly oxLDL inhibits this transcription factor.40 42 In one of these studies, the appearance of an oxLDL-induced NF-{kappa}B band was observed that was not characterized further.40 In human smooth muscle cells, mildly and highly oxLDL had no effect on the DNA-binding activity of NF-{kappa}B.41 However, a 2.5-hour preincubation with extensively oxLDL significantly inhibited the LPS-induced activation of this transcription factor, whereas mildly oxLDL showed only a weak effect.41 All these data, taken together with our results, indicate that various cell types in culture apparently react differently to oxLDL and/or that the biological effects of mildly oxLDL and highly oxLDL are different. For instance, the longer preincubation period required to inhibit the LPS-induced NF-{kappa}B activation in our system compared with the relatively short exposure time found to be effective in smooth muscle cells41 could be due to differences between monocytic and smooth muscle cells but also a result of the fact that we used mildly oxLDL.

The oxLDL-induced activation of NF-{kappa}B in our study was accompanied by a dramatic increase in the production of the NF-{kappa}B target gene, IL-8.5 Using reporter constructs, we demonstrated that oxLDL significantly induced IL-8 promoter-dependent transcription. These data suggest that the NF-{kappa}B activated by oxLDL induces transcription of the IL-8 gene, leading to the upregulation of IL-8 expression in monocytic cells. In addition, it has been demonstrated that oxLDL stimulates or enhances the expression of the NF-{kappa}B–regulated genes IL-1ß31 and tissue factor33 in cells of monocytic origin.

ROI such as H2O2 have recently been implicated as one of the intracellular second-messenger molecules that induce NF-{kappa}B activation.5 7 48 51 Cell treatment with H2O2 has been demonstrated to activate NF-{kappa}B and induce {kappa}B-dependent gene expression.49 Cell lines stably overexpressing the H2O2 degrading enzyme catalase are deficient in activation of NF-{kappa}B in response to TNF and okadaic acid.52 In contrast, stable overexpression of cytoplasmic superoxide dismutase, which enhances the production of H2O2 from superoxide, potentiated NF-{kappa}B activation.52 In our study, the activation of NF-{kappa}B by oxLDL could be inhibited by the antioxidant and H2O2 scavenger PDTC in a dose-dependent manner. Therefore, it is interesting to hypothesize that oxLDL-induced signaling leads to the production of ROI followed by the activation of NF-{kappa}B.

The oxLDL-induced activation of NF-{kappa}B was accompanied by a depletion of I{kappa}B-{alpha}, both of which were inhibited by the proteasome inhibitor PSI. This suggests that exposure to oxLDL induces I{kappa}B-{alpha} proteolysis leading to NF-{kappa}B activation. The initial depletion of I{kappa}B-{alpha} was followed by a slight and transient increase in the level of this inhibitor in our experiments. It should be mentioned that a number of functional NF-{kappa}B regulatory sequences have been found in the I{kappa}B-{alpha} promoter and that the gene encoding this inhibitor is itself regulated by NF-{kappa}B.5 6 Therefore, the increase in the level of I{kappa}B-{alpha} in cells exposed to oxLDL is likely to be the result of NF-{kappa}B–mediated expression of the I{kappa}B-{alpha} gene. Long-term exposure to oxLDL for 24 hours inhibited the LPS-induced NF-{kappa}B activation and target gene expression in our study. Under these conditions, our data demonstrated that the LPS-induced depletion of I{kappa}B-{alpha} was not evident in cells preexposed to oxLDL for 24 hours, whereas in the absence of modified lipoproteins, the expected proteolytic degradation of I{kappa}B-{alpha} after activation was observed.5 7 This suggests that long-term incubation with oxLDL inhibits pathways for NF-{kappa}B activation at the level of I{kappa}B-{alpha} degradation (eg, inhibition of the proteasome) and/or mechanisms located upstream of this protease step.53

Recently, we have shown the presence of activated NF-{kappa}B in some but not all macrophages present in the atherosclerotic lesion.11 How is this possible in view of the presence of oxLDL in the lesion, since we have shown in the present study that the long-term exposure of macrophages to oxLDL actually inhibits the NF-{kappa}B system? Several potential explanations arise: Despite a significant inhibition of LPS-induced NF-{kappa}B activity by long-term exposure to oxLDL in our study, a modest activation of this transcription factor above the base line level remained under these conditions (ie, in the presence of oxLDL plus LPS). The inhibition of NF-{kappa}B activation by long-term incubation with oxLDL may also represent an autoregulatory mechanism53 and allow restimulation after a certain time span. Furthermore, it is not known whether oxLDL is able to inhibit the activation of NF-{kappa}B by all of the numerous known stimuli for this transcription factor in the atherosclerotic lesion including TNF-{alpha}, IL-1ß, growth factors, thrombin, and fibronectin,8 9 10 which may induce different signaling pathways. Furthermore, macrophages should also be able to phagocytose the oxLDL12 29 and therefore remove these lipoproteins from their close environment, thereby preventing a long exposure to oxLDL that presumably would be highly toxic. There are also lipid-poor atherosclerotic regions12 in which the macrophages would be less exposed to oxLDL. Finally, the various subpopulations of macrophages that exist in sites of chronic inflammatory processes such as atherosclerosis may respond differently to oxLDL.9 12 29 In conclusion, as in any environment of chronic inflammation, there may be both activating and inhibiting forces in the atherosclerotic lesion which positively as well as negatively (dys)regulate the NF-{kappa}B-system. Future experiments should address the question to what extent both activation and inhibition of NF-{kappa}B affect the process of atherogenesis.


*    Selected Abbreviations and Acronyms
 
EMSA = electrophoretic mobility shift assay
IL = interleukin
LPS = lipopolysaccharide
NF-{kappa}B = nuclear factor-{kappa}B
oxLDL = oxidized low-density lipoprotein
PDTC = pyrrolidine dithiocarbamate
PSI = proteasome inhibitor N-benzyloxycarbonyl-Ile-Glu-(O-t-Bu)-Ala-Leucinal
RLU = relative light units
ROI = reactive oxygen intermediates
TNF = tumor necrosis factor


*    Acknowledgments
 
This work was supported by grants from the Deutsche Forschungsgemeinschaft (Br 1026/3-1, SFB 469, Dr K. Brand) and by NIH grant HL-48872 (Dr N. Mackman). We are very grateful to Dr C.A. Banka for helpful discussion, Dr Bruno Bonetti for providing cDNA probes, and Dr N. Marx and C. Rokitta for valuable contributions.

Received September 30, 1996; accepted May 2, 1997.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Lenardo MJ, Baltimore D. NF-{kappa}B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.[Medline] [Order article via Infotrieve]
  2. Baeuerle PA. The inducible transcription activator NF-{kappa}B: regulation by distinct protein subunits. Biochim Biophys Acta. 1991;1072:63-80.[Medline] [Order article via Infotrieve]
  3. Grilli MJ, Chiu JS, Lenardo MJ. NF-{kappa}B and Rel: participants in a multiform transcriptional regulatory system. Int Rev Cytol. 1993;143:1-62.[Medline] [Order article via Infotrieve]
  4. Thanos D, Maniatis T. NF-{kappa}B: a lesson in family values. Cell. 1995;80:529-532.[Medline] [Order article via Infotrieve]
  5. Baeuerle PA, Henkel T. Function and activation of NF-{kappa}B in the immune system. Annu Rev Immunol. 1994;12:141-179.[Medline] [Order article via Infotrieve]
  6. Cheng QC, Cant A, Moll T, Hofer-Warbinek R, Wagner E, Birnstiel ML, Bach FH, de Martin R. NF-{kappa}B subunit-specific regulation of the I{kappa}B-{alpha} promoter. J Biol Chem. 1994;269:13551-13557.[Abstract/Free Full Text]
  7. Müller JM, Ziegler-Heitbrock HWL, Baeuerle PA. Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology. 1993;187:233-256.[Medline] [Order article via Infotrieve]
  8. Collins T. Endothelial nuclear factor-{kappa}B and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.[Medline] [Order article via Infotrieve]
  9. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488-2496.[Abstract/Free Full Text]
  10. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of NF-kappa B in atherogenesis. Exp Physiol. 1997;82:297-304.[Abstract]
  11. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-1722.[Medline] [Order article via Infotrieve]
  12. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.[Medline] [Order article via Infotrieve]
  13. Barath P, Fishbein MC, Lao J, Bernson J, Helfaut RH, Forrester JS. Tumor necrosis factor gene expression in human vascular smooth muscle cells detected by in vitro hybridization. Am J Pathol. 1990;137:503-509.[Abstract]
  14. Hiscott J, Marois J, Garoufalis J, D'Addarion M, Roulston A, Kwan I, Pepin N, Lacoste J, Nguyen H, Bensi G, Fenton M. Characterization of a functional NF-kappa B site in the human interleukin-1ß promoter: evidence for a positive autoregulatory loop. Mol Cell Biol. 1993;13:6231-6240.[Abstract/Free Full Text]
  15. Terkeltaub R, Banka CL, Solan J, Santoro D, Brand K, Curtiss LK. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb. 1994;14:47-53.[Abstract/Free Full Text]
  16. Rosenfeld ME, Ylä-Herttuala S, Lipton BA, Ord VA, Witztum JL, Steinberg D. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol. 1992;140:291-300.[Abstract]
  17. Clinton SK, Underwood R, Haynes L, Sherman ML, Kufe DW, Libby P. Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140:301-316.[Abstract]
  18. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991;88:5252-5256.[Abstract/Free Full Text]
  19. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified LDL induces monocyte chemotactic protein-1 in human endothelial and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134-5138.[Abstract/Free Full Text]
  20. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci U S A. 1989;86:2839-2843.[Abstract/Free Full Text]
  21. Brand K, Fowler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol. 1991;11:4732-4738.[Abstract/Free Full Text]
  22. Mackman N, Brand K, Edgington TS. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor {kappa}B binding sites. J Exp Med. 1991;174:1517-1526.[Abstract/Free Full Text]
  23. Drake T, Hannani K, Fei H, Lavi S, Berliner JA. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol. 1991;138:601-607.[Abstract]
  24. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991;251:788-791.[Abstract/Free Full Text]
  25. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule-1 promotor. J Exp Med. 1992;176:1583-1593.[Abstract/Free Full Text]
  26. Iademarco MF, McQuillan JJ, Rosen GD, Dean DC. Characterization of the promotor for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem. 1992;267:16323-16329.[Abstract/Free Full Text]
  27. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Am J Pathol. 1992;140:665-673.[Abstract]
  28. Duyao MP, Buckler AJ, Sonenshein GE. Interaction of an NF-{kappa}B like factor with a site upstream of the c-myc promotor. Proc Natl Acad Sci U S A. 1990;87:4727-4731.[Abstract/Free Full Text]
  29. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
  30. Lesnik P, Dentan C, Vonica A, Moreau M, Chapman MJ. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation. Arterioscler Thromb Vasc Biol. 1995;15:1121-1130.[Abstract/Free Full Text]
  31. Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res. 1994;35:417-427.[Abstract]
  32. Lipton BA, Parthasarathy S, Ord VA, Clinton SK, Libby P, Rosenfeld ME. Components of the protein fraction of oxidized low density lipoprotein stimulate interleukin-1 alpha production by rabbit arterial macrophage-derived foam cells. J Lipid Res. 1995;36:2232-2242.[Abstract]
  33. Brand K, Banka CL, Mackman N, Terkeltaub RA, Fan ST, Curtiss LK. Oxidized low density lipoprotein enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb. 1994;14:790-797.[Abstract/Free Full Text]
  34. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature. 1990;344:254-257.[Medline] [Order article via Infotrieve]
  35. Rajavashisth TB, Yamada H, Mishra NK. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Arterioscler Thromb Vasc Biol. 1995;15:1591-1598.[Abstract/Free Full Text]
  36. Hamilton TA, Ma G, Chisholm GM. Oxidized low density lipoprotein suppresses the expression of tumor necrosis factor-{alpha} mRNA in stimulated murine peritoneal macrophages. J Immunol. 1990;144:2343-2350.[Abstract]
  37. Fong LG, Fong TAT, Cooper AD. Inhibition of lipopolysaccharide-induced interleukin-1ß mRNA expression in mouse macrophages by oxidized low density lipoprotein. J Lipid Res. 1991;32:1899-1910.[Abstract]
  38. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471-478.
  39. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem. 1995;270:17050-17055.[Abstract/Free Full Text]
  40. Shackelford RE, Misra UK, Florine-Casteel K, Thai SF, Pizzo SV, Adams DO. Oxidized low density lipoprotein suppresses activation of NF-{kappa}B in macrophages via a pertussis toxin-sensitive signaling mechanism. J Biol Chem. 1995;270:3475-3478.[Abstract/Free Full Text]
  41. Ares MPS, Kallin B, Eriksson P, Nilsson J. Oxidized LDL induces transcription factor activator protein-1 but inhibits activation of nuclear factor-{kappa}B in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995;15:1585-1590.
  42. Ohlsson BG, Englund MCO, Karlsson ALK, Knutsen E, Erixson C, Skribeck H, Liu Y, Bondjers G, Wiklund O. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-{kappa}B to DNA and the subsequent expression of tumor necrosis factor-{alpha} and interleukin-1ß in macrophages. J Clin Invest. 1996;98:78-89.[Medline] [Order article via Infotrieve]
  43. Brand K, Mackman N, Curtiss LK. Interferon-{gamma} inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest. 1993;91:2031-2039.
  44. Parthasarathy S, Steinbrecher UP, Barnett J, Witztum JL, Steinberg D. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci U S A. 1985;82:3000-3004.[Abstract/Free Full Text]
  45. Banka CL, Black AS, Dyer CA, Curtiss LK. THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. J Lipid Res. 1991;32:35-43.[Abstract]
  46. Wallin B, Rosengren B, Schertzer HG, Camejo G. Lipoprotein oxidation and measurement of thiobarbiturate acid reacting substances formation in a single microtiter plate; its use for evaluation of antioxidants. Anal Biochem. 1993;208:10-15.[Medline] [Order article via Infotrieve]
  47. Traenckner EBM, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-{kappa}B and stabilizes a newly phosphorylated form of I{kappa}B-{alpha} that is still bound to NF-{kappa}B. EMBO J. 1994;13:5433-5441.[Medline] [Order article via Infotrieve]
  48. Ziegler-Heitbrock HWL, Sternsdorf T, Liese J, Belohradsky B, Weber C, Wedel A, Schreck R, Baeuerle PA, Ströbel M. Pyrrolidine dithiocarbamate inhibits NF-{kappa}B mobilization and TNF production in human monocytes. J Immunol. 1993;151:6986-6993.[Abstract]
  49. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-{kappa}B transcription factor and HIV-1. EMBO J. 1991;10:2247-2258.[Medline] [Order article via Infotrieve]
  50. Schütze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Krönke M. TNF activates NF-{kappa}B by phosphatidylcholine-specific phospholipase C-induced `acidic' sphingomyelin breakdown. Cell. 1992;71:765-776.[Medline] [Order article via Infotrieve]
  51. Weber C, Erl W, Pietsch A, Ströbel M, Ziegler-Heitbrock HWL, Weber PC. Anti-oxidants inhibit monocyte adhesion by suppressing nuclear factor-{kappa}B mobilization and induction of vascular cell adhesion molecule-1 in endothelial cells stimulated to generate radicals. Arterioscler Thromb. 1994;14:1665-1673.[Abstract/Free Full Text]
  52. Schmidt KN, Amstad P, Cerutti P, Baeuerle PA. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-{kappa}B. Chem Biol. 1995;2:13-22.[Medline] [Order article via Infotrieve]
  53. Finco TS, Baldwin AS. Mechanistic aspects of NF-{kappa}B regulation: the emerging role of phosphorylation and proteolysis. Immunity. 1995;3:263-272.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Cappello, B. Saugel, K. C. Huth, A. Zwergal, M. Krautkramer, C. Furman, M. Rouis, B. Wieser, H. W. Schneider, D. Neumeier, et al.
Ozonized Low Density Lipoprotein (ozLDL) Inhibits NF-{kappa}B and IRAK-1-Associated Signaling
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 226 - 232.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
C. Antoniades, D. Tousoulis, K. Marinou, C. Vasiliadou, C. Tentolouris, G. Bouras, C. Pitsavos, and C. Stefanadis
Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines.
Am. J. Clinical Nutrition, October 1, 2006; 84(4): 781 - 788.
[Abstract] [Full Text] [PDF]